The company shared new findings for its TriClip system at ACC 2026 in New Orleans. Results from the Tri.Fr study demonstrated a significant reduction in HFH risk relative to medical therapy.
TriClip transcatheter edge-to-edge repair (TEER) offers an option for those who aren’t good candidates for surgery and continue to have symptoms or persistent tricuspid regurgitation (TR) despite treatment with medical therapy. Delivered through a vein in the leg, the TriClip TEER technology clips together a portion of leaflets. It repairs the tricuspid valve and helps blood flow in the right direction without the need for open-heart surgery.
According to Abbott, TriClip leverages the same clip-based technology as its leading MitraClip device for mitral regurgitation (MR). However, its unique design specifically addresses the tricuspid valve’s complex anatomy.
The system received FDA approval in April 2024. Last year, Abbott reported sustained improvements with the system in the TRILUMINATE trial.
Now, in Tri.Fr, Abbott reports a 48% reduction in HFH hospitalization relative to medical therapy when using TriClip TEER. The company also said it observed a 44% reduction in major cardiovascular events relative to medical therapy.
TriClip safely reduces HFH risk, Abbott says, with Tri.Fr following TRILUMINATE as the second trial to demonstrate this.
